| Name | Title | Contact Details |
|---|
Pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart.
Headquartered in Louisville, Kentucky, with nearly $2 billion in annual revenues, PharMerica is one of the largest and fastest growing institutional pharmacy companies in America. We are a premier pharmacy services provider dedicated to providing innovative solutions for customers and patients. At PharMerica, you can choose your career path – hospital pharmacy, long term care pharmacy, corporate and non-clinical opportunities. We employ some of the industry`s best and brightest innovators and clinicians. With more than 100 long-term care pharmacies in over 45 states nationwide, PharMerica employs approximately 5,500 dedicated employees and pharmacy professionals. We offer our staff the opportunity to learn the business and cross train in other areas to provide a catalyst for their career growth within PharMerica. We also recruit our next generation of leaders by hiring new graduates from some of the nation`s top pharmacy and business schools. In addition, we offer educational opportunities through internships and our management training program. As a fast growing organization, we can provide you with the opportunity to kick start your career or advance your skills using some of the industry`s state-of-the-art technology. We foster an environment that encourages our high performers. Because we are a national company, we can provide opportunities for employees that desire to relocate. In addition, we offer a comprehensive benefits package that supports your quality of life.
Merz Pharmaceuticals is a Greensboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Michael's Pharmacy is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EUSA Pharma is a specialty pharma company with a strong and growing portfolio of specialty hospital medicines. It has been built through the acquisition of Talisker Pharmaceuticals in July 2006 and OPi in March 2007. Our primary marketed products are